

Effect of lycosomal formulations of lycopene and resveratrol chaperoned with phosphatidylcholine on progression and outcomes of Hepatitis C.

ACTRN12615000645550

Status	RECRUITING
Phase	Phase 2
Sponsor	Lycotec Ltd, Cambridge, UK
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (3)

- Consented males or females 18-65 years of age and testing positive for any HCV genotype on the standard interferon therapy.
- Newly diagnosed cases of Hepatitis C as well as patients with chronic Hepatitis C patients positive in quantitative and qualitative PCR with concomitant increase of liver-specific enzymes in serum (>2 folds over control level).
- Stable clinical conditions not requiring emergency care

Exclusion (12)

- Clinically significant infection, other than HCV, defined as any acute viral, bacterial, or fungal infection, which requires specific therapy.
- Co-infections with Hepatitis B virus and Human immunodeficiency virus (HIV).
- Received any investigational drug agent(s) within 28-days of entry into study.
- Any known pre-existing medical condition that could interfere with the subject's participation in the protocol, including serious psychiatric disorders, CNS trauma or active seizure disorders requiring medication, poorly controlled diabetes mellitus, significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, recent myocardial infarction, severe hypotension, or significant arrhythmia).
- Subjects with ECG showing clinically significant abnormalities.

... and 7 more (see full listing online)

Locations (2 total)

Cambridge, United Kingdom
Tashkent, Uzbekistan